53 results about "Sustained release pellets" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a meloabalin besylate double-release preparation and a preparation method thereof. Comprising a quick-release pellet and a sustained-release pellet, and the quick-release pellet and the sustained-release pellet are wrapped in a hollow capsule; the quick-release pellet comprises a quick-release blank pellet core, a quick-release drug layer and a quick-release film coating layer; the sustained-release pellet comprises a sustained-release blank pellet core, a sustained-release drug layer, a sustained-release layer and a sustained-release film coating layer. According to the invention, the stable blood concentration is obtained while the medicine effect takes effect quickly, the medicine taking frequency is reduced, convenience is brought to patients, and the compliance is improved. The invention also provides a preparation method thereof.

The invention provides a medicine composition containing vinloxacin hydrochloride. The medicine composition comprises a quick-release pellet and a sustained-release pellet. The pharmaceutical composition provided by the invention has the advantages of good stability, capability of simultaneously meeting the specific requirement on in-vitro dissolution of the viloxin hydrochloride, small variety and dosage of auxiliary materials, higher safety and suitability for preparation of a preparation. And the protective layer is sprayed on the outer surface of the sustained-release layer, so that the advantages of weakening the electrostatic interaction of the pellets and preventing the particles from caking in the aging process are further achieved. In addition, the invention also provides a preparation method of the pharmaceutical composition, and the method has the advantages of high drug application rate, less fine powder, no filter bag and spray gun head blockage phenomenon, and suitableness for industrial production and application.

Disclosed are an ibuprofen pharmaceutical composition, and a preparation method therefor and the use thereof. The ibuprofen pharmaceutical composition comprises the following components: sustained-release pellets and immediate-release pellets, wherein the sustained-release pellets comprise ibuprofen, a filler and an adhesive; and the immediate-release pellets comprise ibuprofen, a filler, a suspending agent, a disintegrant, a flavoring agent and a pH regulator. The ibuprofen pharmaceutical composition takes effect quickly and can maintain a therapeutic effect for a long time. The administration compliance of children, elderly people and people with dysphagia can be effectively improved, and the administration frequency is reduced. A dry deposition particle has a wide loading range, and the presence of the dry deposition particle during drug storage and transportation is beneficial for maintaining the stability during drug storage and transportation. In addition, the ibuprofen pharmaceutical composition has the advantages of a simple preparation process, stable properties and convenient administration, and is suitable for industrial production.

The invention discloses a lacidipine film-controlled sustained-release pellet capsule and a preparation method thereof, relates to the technical field of medicines, and aims to solve the problem of release reduction caused by film aging of a lacidipine film-controlled sustained-release pellet prepared by an aqueous dispersion coating. The preparation method comprises the following steps: respectively weighing a lacidipine bulk drug, a polymer carrier material and a plasticizer according to a prescription amount, grinding and uniformly mixing to prepare the lacidipine solid dispersion. A sustained-release coating film of the pellet capsule contains Eurdragit RL30D, a plasticizer triethyl citrate and an anti-sticking agent talcum powder, and a pellet core contains croscarmellose sodium and an excipient. According to the lacidipine solid dispersion solid preparation provided by the invention, lacidipine exists in the carrier material in a microcrystalline state, an amorphous state, a colloidal dispersion state or a molecular dispersion state, so that the lacidipine solid dispersion solid preparation has high dispersity, the dissolution speed of a medicine is accelerated, the absorption of the medicine can be promoted, and the bioavailability is improved.

The invention discloses a glycocholic acid sustained release preparation and a production process thereof. The glycocholic acid sustained-release preparation comprises glycocholic acid sustained-release pellets, and the preparation method of the glycocholic acid sustained-release preparation comprises the following steps: firstly, preparing glycocholic acid and auxiliary materials into a drug-containing pellet core according to a formula, then coating the drug-containing pellet core with a sustained-release material to obtain the sustained-release pellets, and finally, filling the sustained-release pellets into capsules to obtain the glycocholic acid sustained-release preparation. The preparation method comprises the following steps: carrying out wet granulation-extrusion rolling to obtain wet pills, drying, and coating with a fluidized bed to obtain the glycocholic acid sustained-release pellets. The quality of the drug-loaded pellet is controlled according to indexes such as roundness, bulk density, yield and the like, the drug release effect of the sustained-release pellet is evaluated according to the dissolution rate, and the release mechanism and the initial stability of the glycocholic acid sustained-release pellet are investigated. The invention has the advantages of favorable sustained-release effect, reduced medication frequency, simple and feasible preparation process, favorable reproducibility and favorable drug stability, is suitable for industrial production, aims at supporting the research and development of the compound sustained-release drug, and has obvious social and economic benefits.

The invention provides a sustained-release pellet containing gamma-aminobutyric acid, the sustained-release pellet comprises a pellet core and a coating layer wrapping the pellet core, the pellet core contains a physiologically active substance, and the physiologically active substance is gamma-aminobutyric acid; the pellet core comprises the following components in parts by weight: 15-40 parts of gamma-aminobutyric acid, 30-55 parts of a filling agent, 1-30 parts of a lubricating agent and 0.5-5 parts of an anti-caking agent; the filling agent comprises at least one of microcrystalline cellulose, powdery cellulose, starch and derivatives thereof, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, sugar or sugar alcohol and fruit and vegetable powder; the lubricant comprises at least one of talcum powder, magnesium stearate, stearic acid, glycerol and leucine; the anti-caking agent comprises at least one of magnesium carbonate, tricalcium phosphate, calcium hydrophosphate and silicon dioxide.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

The invention relates to an aldenafil sustained-release pellet as well as a preparation method and application thereof. The aldenafil sustained-release pellet sequentially comprises the following components in percentage by mass: 60-85% of a drug-containing pellet core, 0.5-3% of an isolating layer, 2-8% of an acidic coating layer and 5-30% of a sustained-release coating layer from inside to outside, the medicine-containing pill core comprises the aldenafil and / or pharmaceutically acceptable salt or ester thereof, a diluent and an adhesive; the isolating layer comprises a film coating material; the acidic coating layer comprises an organic acid and an acidic polymer; the organic acid accounts for 0.5%-5% of the mass of the aldenafil sustained-release pellet; the sustained-release coating layer comprises a sustained-release material. The aldenafil sustained-release pellet can provide an acidic microenvironment in time, meanwhile, the acidic buffering capacity of the microenvironment is improved, the aldenafil sustained-release pellet can be dissolved out in different dissolution media within 12-24 h without pH dependence, the aldenafil sustained-release pellet can be completely dissolved out in an alkaline intestinal environment, absorption of a sustained-release preparation is not affected, and the aldenafil sustained-release pellet has high bioavailability.

The invention discloses an ibuprofen pharmaceutical composition as well as a preparation method and application thereof. The ibuprofen pharmaceutical composition comprises the following components: a sustained-release pellet and a quick-release pellet, wherein the sustained-release pellet comprises ibuprofen, a filling agent and an adhesive; the quick-release pellet comprises ibuprofen, a filling agent, a suspending aid, a disintegrating agent, a flavoring agent and a pH regulator. The ibuprofen pharmaceutical composition takes effect quickly, can maintain the treatment effect for a long time, can effectively improve the administration compliance of children, old people and people with dysphagia, and reduces the administration frequency; the dry suspension particles are large in loading range and exist in the form of the dry suspension particles in the storage and transportation processes, so that the stability of the medicine in the storage and transportation processes can be ensured; the medicine is simple in preparation process, stable in property, convenient to take and suitable for industrial production.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The application discloses a slow-release micro-pellet containing gamma-aminobutyric acid and a preparation method and application thereof. Gamma-aminobutyric acid is wrapped in a mucosal adhesion material in a fluidized bed to form a micro-pellet, and the micro-pellet is dispersed in an aqueous alginate solution to form a micro-pellet with a size of about 1-10 mm through calcium ion cross-linking. The slow-release micro-pellet overcomes the shortcomings of a product without cross-linked alginate, such as poor slow-release effect and easy burst release of active ingredients, has a biological membrane adhesion property, can realize stable release of GABA in a small intestine for at least 8 hours, presents obvious slow-release characteristics in a beagle dog in vivo, significantly delays a peak time, significantly reduces a peak concentration, significantly prolongs an elimination half-life, keeps a blood drug concentration stable and small fluctuation, and significantly improves a relative oral bioavailability. The application has the advantages of a soft and elastic texture after water absorption, chewability, and flexible and various taking modes. In addition, the application has a simple preparation process and can realize industrial production.

The invention provides a nicotine sustained-release capsule, the nicotine sustained-release capsule comprises a content, the content comprises a sustained-release pellet, the sustained-release pellet comprises an active core, a first coating layer and a second coating layer which are sequentially arranged from inside to outside, the active core comprises at least one of nicotine or a nicotine derivative, the first coating layer comprises a first adhesive, and the second coating layer comprises a second adhesive. The second coating layer comprises a second adhesive, and the second coating layer is an enteric coating; through the design of the nicotine sustained-release capsule dosage form, the drug release rate can be delayed, the stable blood concentration can be maintained, the drug effect duration can be prolonged, the smoking process of'low-dose sustained release 'can be simulated, and the emotion and physiological reaction in the smoking cessation process can be improved; in addition, the design of the double-layer coating is also helpful for stabilizing the fluctuation of the blood concentration, and a safer, more continuous and milder nicotine release process is realized.

The application belongs to the technical field of pharmaceutical preparations, and discloses a soft capsule preparation containing alfacalcidol and a preparation method thereof. The soft capsule preparation comprises a soft capsule shell and content filled in the soft capsule shell, and the content is composed of a drug-containing oil phase and alfacalcidol sustained-release pellets dispersed in the oil phase. The drug-containing oil phase comprises immediate-release alfacalcidol dissolved in an oily base. The sustained-release pellets comprise a blank pellet core, a drug-loaded layer and a separation layer, and the separation layer comprises a combined coating material of Eudragit RS30D and Eudragit RL30D. After oral administration, the alfacalcidol in the oil phase is rapidly released to achieve immediate effect, and the alfacalcidol in the sustained-release pellets is slowly released to maintain the steady state of blood drug concentration. The soft capsule preparation of the application realizes the dual-phase drug release behavior of immediate release and sustained release in the same soft capsule, so that the blood drug concentration is smooth and controllable within 24 hours, the steady state of blood drug concentration is maintained, the frequency of drug administration is reduced, and the risk of side effects such as hypercalcemia is reduced.

The invention discloses budesonide enteric-coated sustained-release pellets and a preparation method thereof, and belongs to the technical field of biological medicines. The budesonide enteric-coated and sustained-release pellet sequentially comprises a medicine-containing pellet core, a sustained-release layer and an enteric-coated layer from inside to outside, the drug-containing pill core comprises budesonide, a filler, an adhesive, an acidic agent and a lubricant; the sustained-release layer comprises the following components: a retardant, a plasticizer and an anti-sticking agent; the enteric-coated layer comprises the following components: an enteric-coated material, a plasticizer and an anti-sticking agent. The budesonide enteric-coated sustained-release pellet is prepared by the following steps: preparing budesonide and auxiliary materials into a drug-containing pellet core through an extrusion rolling process, and then coating the drug-containing pellet core with a sustained-release layer and an enteric-coated layer in sequence through a fluidized bed coating, thereby obtaining the budesonide enteric-coated sustained-release pellet. The budesonide enteric-coated and sustained-release pellet cannot be released and absorbed in the stomach, the effect gradually starts after the budesonide enteric-coated and sustained-release pellet reaches the intestinal tract, and the budesonide enteric-coated and sustained-release pellet keeps a proper concentration level in in-vivo blood, so that targeted continuous treatment of inflammatory intestinal diseases is facilitated.

The invention relates to a high-content 5-aminolevulinic acid sustained-release pellet, which comprises the following components: 5-aminolevulinic acid phosphate; microcrystalline cellulose (MCC PH-102); hydroxypropyl cellulose (HPC-SL); 2-5% of pregelatinized starch; sodium carboxymethyl starch (CMS-Na); sucrose; the drug loading capacity is 60 + / -2%, and the bulk density is 0.65-0.75 g / cm < 3 >.

The invention relates to a glipizide controlled-release tablet, the controlled-release tablet comprises a sustained-release pellet and pharmaceutically acceptable auxiliary materials, the sustained-release pellet comprises (a) a blank pellet core, (b) a drug coating layer wrapping the blank pellet core, and (c) a sustained-release coating layer wrapping the drug coating layer; the in-vitro release degree similarity factor f2 of the controlled release tablet and a commercially available glipizide osmotic pump tablet, namely, reiligenin, is greater than or equal to 50. According to the glipizide controlled release tablet, the defects that in the preparation process of commercially available glipizide osmotic pump tablets, a large amount of acetone is used as a coating solvent, and laser drilling has high requirements on production equipment and technological process are overcome, the production process is simple, and the product reproducibility is good.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising a) immediate release granules comprising i. an active ingredient selected from the group consisting of valproic acid, valproate semisodium, sodium valproate and magnesium valproate, and ii. a filler, and b) sustained release pellets comprising: i. pellet cores comprising: (1) an active ingredient selected from the group consisting of valproic acid, valproate semisodium, sodium valproate, and magnesium valproate, and (2) a filler, ii. a subcoat provided on the pellet cores, the content of the subcoat being 10-20 wt% based on the weight of the pellet cores, and the subcoat comprising a film forming agent, and iii. a sustained release coating provided on the subcoat, the content of the sustained release coating being 25-100 wt% based on the weight of the pellet cores coated with the subcoat, and the sustained release coating comprising a film forming agent, wherein the amount of active ingredient in the immediate release granules makes up 70-80 wt% of the total weight of active ingredient in the pharmaceutical composition, and the amount of active ingredient in the sustained release pellets makes up 20-30 wt% of the total weight of active ingredient in the pharmaceutical composition. In further aspects the present invention relates to a method of producing the pharmaceutical composition and the pharmaceutical composition for use in a method of pretreating cancer.

The invention discloses an icariin enteric-coated sustained-release pellet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations, and the pellet sequentially comprises a drug-containing pellet core, a sustained-release coating layer and an enteric coating layer from inside to outside. The pellet core contains icariin, microcrystalline cellulose, an adhesive, a disintegrating agent and an antioxidant; the sustained-release coating layer takes ethyl cellulose as a sustained-release material; the enteric coating layer takes acrylic resin and sodium alginate as dual pH response materials, the 2-hour release rate of the pellet in a hydrochloric acid solution with the pH value of 1.0 is less than 10%, the pellet presents near-zero-order release kinetics in a buffer solution with the pH value of 6.8 within 12 hours, the problems that icariin is degraded in gastric acid, the bioavailability is low and the half-life period is short are solved, the icariin can be administrated twice a day, and the bioavailability is high. The traditional Chinese medicine composition is used for treating kidney-yang deficiency type impotence, premature ejaculation and infertility.

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The present invention relates to the technical field of medical, dental or cosmetic preparations, and in particular to a mesalazine enteric-coated sustained-release micro-pill and a preparation method thereof. The mesalazine enteric-coated sustained-release micro-pill comprises the following components: mesalazine, microcrystalline cellulose, a modified guar gum inclusion agent, a binder, and ethyl cellulose. The present invention also provides a preparation method thereof. Compared with the prior art, the enteric-coated sustained-release micro-pill prepared by the present invention has the advantages of intestinal directional release, mildness and no irritation, etc.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising a) immediate release granules comprising i. an active ingredient selected from the group consisting of valproic acid, valproate semisodium, sodium valproate and magnesium valproate, and ii. a filler, and b) sustained release pellets comprising: i. pellet cores comprising: (1) an active ingredient selected from the group consisting of valproic acid, valproate semisodium, sodium valproate, and magnesium valproate, and (2) a filler, ii. a subcoat provided on the pellet cores, the content of the subcoat being 10-20 wt% based on the weight of the pellet cores, and the subcoat comprising a film forming agent, and iii. a sustained release coating provided on the subcoat, the content of the sustained release coating being 25-100 wt% based on the weight of the pellet cores coated with the subcoat, and the sustained release coating comprising a film forming agent, wherein the amount of active ingredient in the immediate release granules makes up 70-80 wt% of the total weight of active ingredient in the pharmaceutical composition, and the amount of active ingredient in the sustained release pellets makes up 20-30 wt% of the total weight of active ingredient in the pharmaceutical composition. In further aspects the present invention relates to a method of producing the pharmaceutical composition and the pharmaceutical composition for use in a method of pretreating cancer.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The invention discloses a metoprolol succinate sustained-release tablet and a preparation method thereof. The tablet comprises a gastric-soluble film coating, a blank filling auxiliary material and a drug-containing sustained-release pellet, the blank filling auxiliary material comprises the following components in parts by weight: 20-40 parts of microcrystalline cellulose, 0.5-2 parts of magnesium stearate and 0.3-1 part of silicon dioxide; the drug-containing sustained-release pellet is composed of a blank pellet core, a drug layer and a sustained-release coating layer, the blank pellet core comprises 10-25 parts of a microcrystalline cellulose pellet core, and the drug layer comprises 25-100 parts of metoprolol succinate, 5-20 parts of lactose and 1-5 parts of povidone K30; the slow-release coating layer is prepared from 3 to 10 parts of ethyl cellulose; by screening the diameter of the pellet and the viscosity of ethyl cellulose, the preparation can realize slow release of drugs, and is low in content of related substances and total impurities, stable in quality and suitable for industrial production.

The invention discloses an oral administration multi-particle composition for intestinal delivery of corticosteroid drugs. The oral administration multi-particle composition comprises sustained release pellets and a delayed release component, the sustained-release pellet comprises a stabilizer-free quick-release drug-containing core, an isolating layer and an alkali-free sustained-release layer. The delayed release component comprises a cellulose capsule and an enteric film. The alkali-free ethyl cellulose sustained-release layer is used in the pharmaceutical composition, so that the degradation of active substances of the medicine can be avoided, and the use of a stabilizer is avoided. Compared with alkali-containing ethyl cellulose, the process flow can be reduced, and the production cost can be reduced.

The invention discloses a collagen composite soft capsule with a three-layer structure as well as a preparation method and application of the collagen composite soft capsule, and belongs to the technical field of composite sustained-release capsules. The capsule contains an outer collagen peptide-gelatin composite rubber layer, a middle Pickering emulsion layer and an inner sustained-release pellet. A compact network is formed on the outer layer under the action of molecules, so that the mechanical strength and the biocompatibility are improved; the middle layer stably loads active ingredients; and the inner-layer sustained-release pellet fixes collagen peptide and integrates various components, so that controlled release is realized. During preparation, a three-layer structure is constructed step by step, physical mixing avoids damage to activity, step-by-step injection keeps each layer independent, and sealing does not need an additional adhesive. The process enhances the strength of the capsule skin, ensures the structural stability, accurately controls the sustained-release structure of the pellet, and improves the gastric acid tolerance and active ingredient stability of the capsule.

The invention relates to a pharmaceutical composition for oral administration. The pharmaceutical composition comprises: a) immediate release particles comprising i. An active ingredient selected from the group consisting of valproic acid, semi-sodium valproate, sodium valproate and magnesium valproate, and ii. A filler, b) sustained release pellets comprising: i. A pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproate, sodium valproate and magnesium valproate, and (2) a filler, ii. A sub-coating disposed on the pellet core, the content of the sub-coating layer is 10-20 wt% based on the weight of the pellet core and the sub-coating layer comprises a film-forming agent, and iii. A slow-release coating layer disposed on the sub-coating layer, the content of the slow-release coating layer is 25-100 wt% based on the weight of the pellet core coated with the sub-coating layer and the slow-release coating layer comprises a film-forming agent, and the content of the slow-release coating layer is 25-100 wt% based on the weight of the pellet core coated with the sub-coating layer. Wherein the amount of the active ingredients in the quick-release particles accounts for 70-80 wt% of the total weight of the active ingredients in the pharmaceutical composition, and the amount of the active ingredients in the slow-release pellets accounts for 20-30 wt% of the total weight of the active ingredients in the pharmaceutical composition. In further aspects, the present invention relates to methods of preparing pharmaceutical compositions and pharmaceutical compositions for use in methods of pre-treating cancer.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and particularly discloses a traditional Chinese medicine composition for treating rheumatoid arthritis and a preparation method thereof. The composition is prepared from tripterygium wilfordii, caulis sinomenii, radix paeoniae alba, liquorice, radix aconiti preparata, pseudo-ginseng, radix clematidis, radix achyranthis bidentatae, gentiana macrophylla and herba pyrolae, and is composed of a quick-release pellet, an enteric-coated sustained-release pellet and a delayed sustained-release pellet. The preparation method comprises the following steps: grouping the raw materials according to efficacy, and respectively performing independent directional extraction and refining to obtain an intermediate; part of the intermediates are subjected to a composite reaction and then used for preparing quick-release pellets; the rest intermediates are respectively used for preparing enteric sustained-release pellets and delayed sustained-release pellets; and finally, mixing the three pellets. According to the composition disclosed by the invention, through a multi-unit sequential controlled release design, sequential treatment on different pathological links of rheumatoid arthritis is realized. In addition, the preparation method disclosed by the invention aims to improve the extraction pertinence of each functional component and the overall quality controllability of the preparation through the combination of functional grouping and an orientation process.

The invention discloses a metoprolol succinate sustained-release tablet and a preparation method thereof, and belongs to the field of pharmaceutical preparations, the metoprolol succinate sustained-release tablet comprises a tablet and a coating layer coated on the surface of the tablet, and the tablet is obtained by tabletting sustained-release pellets and auxiliary materials; the sustained-release pellet comprises a drug-containing pellet core and a sustained-release layer wrapping the drug-containing pellet core; the medicine-containing pill core contains a metoprolol succinate main medicine; the sustained-release layer is formed by coating the drug-containing pellet core with a sustained-release coating material; the medicine-containing pellet core is prepared by the following steps: preparing a soft material from metoprolol succinate, pellet core auxiliary materials and water by using a wet method, and then extruding, rolling and drying to obtain the medicine-containing pellet core. The sustained-release tablet adopts a multi-unit pellet sustained-release technology, so that the medicine is continuously and uniformly released within 24 hours, the blood concentration is more stable, and the heart rate and blood pressure fluctuation are reduced.

The invention provides a multi-release sinomenine hydrochloride sustained-release pellet preparation. The pellet preparation comprises a sustained-release pellet and an enteric-coated pellet in a mass ratio of 1: (1-5), the sustained-release pellet sequentially comprises a pellet core, a medicine carrying layer and a sustained-release layer from inside to outside, the enteric-coated pellet sequentially comprises a pellet core, a medicine carrying layer, a sustained-release layer, an isolating layer and an enteric-coated layer from inside to outside. The multi-release sinomenine hydrochloride sustained-release pellet preparation disclosed by the invention is formed by mixing a sustained-release pellet and an enteric-coated pellet, and the dissolution stability of the pellet preparation is good.

The invention belongs to the field of pharmaceutical preparations, and provides a drug sustained-release capsule for treating liver diseases as well as a preparation method and application of the drug sustained-release capsule. The sustained-release capsule provided by the invention is prepared by filling a capsule with sustained-release pellets. The drug carried by the sustained release pellet is IMM-H014 (Immunoglobulin M-H014). The sustained-release pellet is prepared by coating a sustained-release layer on a drug-loaded pellet, and the drug-loaded pellet has the characteristic of delayed release, and is stable in dissolution rate and good in bioavailability. The traditional Chinese medicine composition is used for treating non-alcoholic fatty liver, hepatitis and drug-induced liver diseases.